what is the link between motivation and dopamine

The short version: dopamine is the molecule of wanting, not liking — it drives motivation and effort, not pleasure itself.

The link between motivation and dopamine is well-established, but it is often misunderstood. Dopamine does not produce the feeling of pleasure or satisfaction. Instead, it drives the pursuit of reward — the wanting, the effort, the motivation to act. A 2008 review of 30 years of research concluded that dopamine antagonists devalue rewards and disrupt motivated behavior without impairing the ability to experience pleasure [1]. This is the core distinction: dopamine is about incentive salience, not hedonic impact.

A large 2025 double-blind study in 100 healthy adults tested this directly [6]. Participants took methylphenidate (a dopamine reuptake inhibitor, like bupropion but stronger), sulpiride (a dopamine blocker), or placebo. Methylphenidate boosted reinforcement learning rates and accuracy, and it reduced the sensitivity to effort — people worked harder for rewards. Sulpiride did the opposite: it reduced working-memory reliance and overall performance [6]. Higher natural dopamine synthesis capacity in the dorsal caudate also predicted better performance, especially under methylphenidate [6]. This is the mechanism: dopamine tunes the brain to pursue rewards and to overcome the cost of effort.

The same pattern shows up in disorders. In obesity, lower striatal D2 receptor availability correlates with higher BMI, suggesting a blunted dopamine signal that makes food less rewarding and drives overeating to compensate [5]. In Parkinson's disease, withdrawing dopamine agonists caused a withdrawal syndrome in 24% of patients, with anxiety, pain, and anhedonia — the opposite of motivation [2]. In depression, dopamine dysregulation in the mesolimbic and mesocortical circuits is a consistent finding, and it is linked specifically to amotivation and anhedonia [4, 3]. A 2020 transdiagnostic review found that striatal-prefrontal connectivity predicts amotivation severity across both schizophrenia and depression [3].

For the drug you are asking about — bupropion — the mechanism fits. Bupropion raises synaptic dopamine and norepinephrine. The evidence here does not test bupropion directly, but the pharmacology predicts it should increase motivation and reduce anhedonia by boosting the same dopamine signal that methylphenidate enhanced in the 2025 study [6]. The question is whether the effect is large enough to matter for a given person, and whether the side-effect burden (seizure risk at high doses, anxiety, insomnia) is worth it. The retrieval does not answer that.

My call: dopamine is the central molecule of motivation, and drugs that raise it (like bupropion) should improve motivation and reduce anhedonia by the same mechanism shown in the methylphenidate study [6]. Confidence: moderate — the mechanism is solid, but the retrieval contains zero bupropion-specific trials, so the effect size and safety profile for your exact drug are not tested here.